I look forward to the information flow and stimulus that may occur from this webinar.
https://www.parentprojectmd.org/eve...erapeutics-phase-ii-trial-final-data-results/
Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into a Phase IIb clinical trial. Please join PPMD and Antisense as we host a webinar Wednesday, June 17 at 1 PM ET to discuss Antisense Therapeutics’ clinical program, as well as next steps in the upcoming Phase IIb trial.
Please submit questions in advance to [email protected] (subject line: Antisense Webinar) by Monday, June 15 at 12 PM ET.
Register >
PPMD webinar
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $242.1K | 2.246M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 47453 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 278209 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |